secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001104659-25-072753
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.02, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune sells cell therapy assets to US WorldMeds for $55M cash plus $30M milestones
--------------------------------------------------------------------------------

- Sold TECELRA, lete-cel, afami-cel, uza-cel to US WorldMeds subsidiary; $55M upfront, up to $30M in milestones.
- Hercules Capital loan of $29.1M paid off, terminating the Loan and Security Agreement.
- Pro forma net gain on sale estimated at $134M after tax; FY2024 pro forma net income of $159.6M vs prior loss.
- Milestones: $5M on lete-cel BLA acceptance, $10M on FDA approval, up to $5M on TECELRA revenue thresholds.
- Pro forma cash increases to $91M from $41M; equity turns positive to $96.7M from negative $37.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/0001104659-25-072753-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925072753/tm2522092d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-072753

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer